Safety and efficacy of imipenem/cilastatin in treatment of complicated urinary tract infections.
Forty-three patients were treated with imipenem/cilastatin for urinary tract infections. The patients were predominantly men (77 percent), 60 years of age or older (81 percent), and had infections caused by Pseudomonas aeruginosa (58 percent). Forty of 43 cases were complicated (including tumor, stone, obstruction, and renal insufficiency). Approximately 33 percent of patients were febrile (temperature greater than 100.4 degrees). All patients received 500 mg of imipenem/cilastatin intravenously every eight hours. Microbiologic eradication was defined as a sterile urine culture sample obtained from two consecutive urine cultures, one during therapy and one five to nine days after therapy. All patients experienced clinical improvement with microbiologic eradication. No patients experienced drug-related clinical adverse effects.
D000328:Adult; D000368:Aged; D015377:Cilastatin; D003521:Cyclopropanes / Q000008:administration & dosage* / Q000009:adverse effects; D004338:Drug Combinations; D005260:Female; D006801:Humans; D015378:Imipenem; D008297:Male; D008875:Middle Aged; D013845:Thienamycins / Q000008:administration & dosage* / Q000009:adverse effects; D014552:Urinary Tract Infections / Q000188:drug therapy*
D003521:Cyclopropanes; D004338:Drug Combinations; D013845:Thienamycins; D015377:Cilastatin; D015378:Imipenem